

VISEARC

Dated: 14 January 2019

MORNING NEWSLETTER

Indices	СМР	%1D
Sensex	36010	-0.27
Nifty	10795	-0.25
BSE-Midcap	15177	-0.13
BSE-Smallcap	14600	-0.19
SGX Nifty	10819	0.02

Indices	СМР	%1D
Sensex	36010	-0.27
Nifty	10795	-0.25
BSE-Midcap	15177	-0.13
BSE-Smallcap	14600	-0.19
SGX Nifty	10819	0.02

Index	FY18	FY19E	FY20E
Sensex EPS	1529	2096	2163
P/E	23	17	16
Nifty EPS	490	637	676
P/E	22	17	16

Global Indices	Current Value	%1D
DowJones	23995	-0.02
Nasdaq	6971	-0.21
DAX	10887	-0.31
Nikkei 225	20359	0.97
FTSE 100	6918	-0.36
Hang Seng	26667	0.55
Shanghai	2554	0.74
Straits Times	3199	0.48

Trading activity in cash Rs Cr			
Date 11 Jan	Net	MTD	FY19
FII	-687	-2374	-74592
DII	123	1323	86823

70.47	0.06%
81.21	0.34%
89.91	0.28%
65.03	0.57%
	81.21 89.91

Corporate Action		
Stock Name	Purpose	Ex Date
Gujarat Gas	Stock Split	15-Jan
NMDC	Buy Back	17-Jan
TCS	Interim Div Rs 4	17-Jan
Bajaj Corp	Interim Div Rs 14	18-Jan
Delta Corpp	Interim Div Rs 0.60	18-Jan

G-Sec Yield	Price	Change%
1yr Bond Yield	6.84	0.13
10yr Bond Yield	7.50	0.29

Market Outlook

Indian markets indicates for a possible flat and cautious trade today on the back of concerns over an ongoing U.S. government shutdown and worries about an economic slowdown in China could dampen a relatively positive sentiments seen in markets last week. Friday closed forming a 'Hammer' kind of pattern on the daily scale and Doji' kind of pattern on the weekly scale hence, market is likely to consolidate further in the coming week followed by a directional move on either side which would largely depend upon earnings releases along with global factors. Technically key support level is placed at 10,739, followed by 10,684. If the index starts moving upward, the key resistance levels to watch out are 10,850 and then 10,905.

Top Domestic News

- Infosys Q3: Profit down 12.2 percent to Rs 3,609 crore versus Rs 4,110 crore; revenue up 3.1 percent at Rs 21,400 crore versus Rs 20,609 crore; \$ revenue up 2.2 percent at \$2,987 million versus \$2,921 million and constant currency revenue growth at 2.7 percent QoQ. Company raises FY19 constant currency revenue growth guidance to 8.5-9 percent from 6-8 percent and maintains EBIT margin guidance at 22-24 percent.
- Infosys: The board approves a special dividend of Rs 4 per share and buyback up to Rs 8,260 crore at maximum Rs 800 per share.
- Cadila Healthcare: Zydus received final approvals from the USFDA for Betamethasone Dipropionate Cream and Amlodipine & Atorvastatin tablets.
- Jammu & Kashmir Bank Q3: Profit rises 43 percent to Rs 103.75 crore versus Rs 72.47 crore; net interest income increases 13 percent to Rs 881.63 crore YoY.
- GNA Axles Q3: Profit rises 41.6 percent to Rs 18 crore versus Rs 12.7 crore; revenue increases 47.5 percent to Rs 246.3 crore versus Rs 167 crore YoY.
- Federal Bank: Executive Director, Ganesh Sankaran steps down
- Yes Bank: Bank announces Brahm Dutt as non-executive part-time chairman.
- Adani Green Energy: Company acquired balance 51 percent equity of Kodangal Solar Parks Private Limited (KSPPL) from FS India Devco Private Limited. With this acquisition, KSPPL has become wholly-owned subsidiary of the company.
- Shree Rama Newsprint Q3: Profit at Rs 9.74 crore versus loss of Rs 3.43 crore; revenue falls to Rs 139.3 crore versus Rs 144 crore YoY.
- Avenue Supermarts Q3: Profit rises to Rs 257.11 crore versus Rs 251.77 crore; revenue jumps to Rs 5,450.94 crore versus Rs 4.093.89 crore YoY.
- HCL Technologies: Audit Committee recommended the appointment of BSR & Associates LLP as the statutory auditors of the company who will hold office for a period of five consecutive years.
- Tata Sponge Iron Q3: Consolidated profit falls to Rs 26.81 crore versus Rs 36 crore; revenue rises to Rs 260.83 crore versus Rs 214.47 crore YoY.
- PNC Infratech: Company received resignation from Rakesh Kumar Gupta from the post of director.
- NTPC: Company to raise Rs 4,000 crore through private placement of secured non-convertible bonds in the nature of debentures at a coupon of 8.30% per annum.
- KNR Constructions: Two wholly owned subsidiary companies have received the financial closure letter from the National Highways Authority of India.
- Sun Pharma Advanced Research: Company had out-licensed XELPROSTM to Sun Pharma in June 2015 and this commercialisation of XELPROSTM, has triggered a milestone payment of \$10 million and sales linked royalties, by Sun Pharma to company.

Global News

Wall Street dipped slightly on Friday, breaking a five-session rally, as energy shares declined and investors looked ahead to earnings season, which kicks off next week with Citigroup, JPMorgan and other big banks.Underpinned by optimism over China-US trade talks and expectations of a slow pace of interest rate hikes from the Federal Reserve, the stock market's winning streak through Thursday added 6 percent to the S&P 500 and left it up about 10 percent from the 20-month low it hit around Christmas. The Dow Jones Industrial Average ended down 0.02 percent at 23,995.95 points, while the Nasdaq Composite dropped 0.21 percent to 6,971.48. The S&P 500 ended down 0.38 points at 2,596.26.

	Results Calender	14-Jan-19
--	------------------	-----------

IBVENTURES, ICICISEC, PRAKASHIND, **TATAMETALIKS**

F&O Ban List

ADANIPOWER, JETAIR



Disclaimer: The views expressed / recommendations made in this report are based on Technical Analysis techniques and could be at variance with the company's / group's views based on fundamental research. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options another derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MEHTA EQUITIES LTD, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MEHTA EQUITIES LTD. The views expressed are those of the analyst and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MEHTA EQUITIES LTD to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478

MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India Tel: +91 22 6150 7101, Fax: +91 22 6150 7102

Email: info@mehtagroup.in Website: www.mehtagroup.in